

Hereditary cancer solutions for a clear understanding of risk

Accessible, actionable insights

Quest Advanced® Oncology offers advanced hereditary cancer risk testing so that you and your patients can understand the risk for cancer, and in some cases, inform treatment and prognosis.

From comprehensive panels to single-gene tests, our complete portfolio of hereditary cancer tests delivers accessible, actionable insights efficiently and affordably.



Leadership in genetic testing provides clarity

- 30+ years of genetic testing experience
- Peer-to-peer consultation with medical and scientific experts
- Genetic counselors ready to provide insight and analysis



Support and services offer a seamless experience

- Our Specialty Testing Services team manages prior authorizations and helps navigate reimbursements to save you time and make our family of genetic tests more accessible
- A network with more than 2,250 Patient Service Centers with flexible collection methods
- Quantum® Solutions makes it easy to order tests and get results when you need them
- In-network with most major health plans, with supplemental financial assistance programs available

Hereditary cancer complete genetic testing menu

Comprehensive Hereditary Cancer Panel

Includes **66 genes**, including emerging genes, to provide deeper genetic insights to help make more informed decisions about your patient's care

Test code	Genes included
38600	<i>APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN1B, CDKN2A, CHEK2, DICER1, EGFR, EPCAM, FANCA, FANCC, FANCM, FH, FLCN, GALNT12, GREM1, HOXB13, MAX, MEN1, MET, MITF, MLH1, MRE11 (MRE11A), MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NTHL1, PALB2, PMS2, POLD1, POLE, POT1, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RECQL, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL, XRCC2</i>

Guideline-Based Hereditary Cancer Panel

32 genes that provide clinically actionable results for hereditary cancers, including moderate-to high-risk for breast, colon, prostate, uterine, melanoma, and other hereditary cancers

Test code	Genes included
38611	<i>APC, ATM, AXIN2, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A (p16,p14), CHEK2, EPCAM, GREM1, HOXB13, MLH1, MSH2, MSH3, MSH6, MUTYH, NF1, NTHL1, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53</i>

Hereditary Breast Cancer Panel

Tests for variants in **18 genes** predominantly associated with breast, prostate, and other tissue cancers

Test code	Genes included
38621	<i>ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53</i>

Hereditary Colorectal Cancer Panel

Tests for variants in **20 genes** associated with increased risk for colorectal cancer

Test code	Genes included
38631	<i>APC, AXIN2, BMPR1A, CDH1, CHEK2, EPCAM, GREM1, MLH1, MSH2, MSH3, MSH6, MUTYH, NTHL1, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53</i>

Hereditary Endocrine Cancer Panel

Tests for variants in **12 genes** associated with increased risk for paragangliomas, pheochromocytomas, and endocrine cancers

Test code	Genes included
38641	<i>FH, MAX, MEN1, NF1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127, VHL</i>

BRCA Panel Plus

Detects variants in **7 genes** associated specifically with breast cancer

Test code	Genes included
92587	<i>BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, TP53</i>

Additional hereditary cancer risk tests

It's important to understand which gene mutations may be the cause of a cancer syndrome. For example, Lynch syndrome is caused by an inherited mutation in 1 of 5 genes. We offer syndrome-specific tests that analyze genes that can be associated with different cancer syndromes, including Lynch syndrome, ovarian, pancreatic, familial adenomatous polyposis, and others.

Test code	Test name	Description
91461	Lynch Syndrome Panel (5 genes)	Detects pathogenic variants in the <i>MLH1</i> , <i>MSH2</i> , <i>MSH6</i> , <i>PMS2</i> , and <i>EPCAM</i> (del/dup only) genes
38651	Nevoid Basal Cell Carcinoma (NBCCS) (Gorlin) Syndrome Panel (<i>PTCH1</i> , <i>SUFU</i>)	Detects variants in <i>PTCH1</i> and <i>SUFU</i>
38661	Tuberous Sclerosis Complex Panel (<i>TSC1</i> , <i>TSC2</i>)	Detects variants in <i>TSC1</i> and <i>TSC2</i>
94053	Juvenile Polyposis Panel (<i>BMPR1A</i> , <i>SMAD4</i>)	Detects pathogenic and variants of unknown significance (VUS) variants in the <i>BMPR1A</i> and <i>SMAD4</i> genes
93945	Hereditary Cancer Single Site(s)	<i>APC</i> , <i>ATM</i> , <i>AXIN2</i> , <i>BAP1</i> , <i>BARD1</i> , <i>BLM</i> , <i>BMPR1A</i> , <i>BRCA1</i> , <i>BRCA2</i> , <i>BRIP1</i> , <i>CDH1</i> , <i>CDK4</i> , <i>CDKN1B</i> , <i>CDKN2A</i> (p16, p14), <i>CHEK2</i> , <i>DICER1</i> , <i>EGFR</i> , <i>EPCAM</i> , <i>FANCA</i> , <i>FANCC</i> , <i>FANCM</i> , <i>FH</i> , <i>FLCN</i> , <i>GALNT12</i> , <i>GREM1</i> , <i>HOXB13</i> , <i>MAX</i> , <i>MEN1</i> , <i>MET</i> , <i>MITF</i> , <i>MLH1</i> , <i>MRE11</i> (<i>MRE11A</i>), <i>MSH2</i> , <i>MSH3</i> , <i>MSH6</i> , <i>MUTYH</i> , <i>NBN</i> , <i>NF1</i> , <i>NTHL1</i> , <i>PALB2</i> , <i>PMS2</i> , <i>POLD1</i> , <i>POLE</i> , <i>POT1</i> , <i>PTCH1</i> , <i>PTEN</i> , <i>RAD50</i> , <i>RAD51C</i> , <i>RAD51D</i> , <i>RECQL</i> , <i>RET</i> , <i>SDHA</i> , <i>SDHAF2</i> , <i>SDHB</i> , <i>SDHC</i> , <i>SDHD</i> , <i>SMAD4</i> , <i>SMARCA4</i> , <i>STK11</i> , <i>SUFU</i> , <i>TMEM127</i> , <i>TP53</i> , <i>TSC1</i> , <i>TSC2</i> , <i>VHL</i> , <i>XRCC2</i>
See description column	Single-gene tests*	<i>APC</i> – 93797, <i>ATM</i> – 38802, <i>BAP1</i> – 38803, <i>BLM</i> – 38804, <i>CDH1</i> – 92568, <i>CDKN2A</i> – 93939, <i>CHEK2</i> – 93940, <i>EPCAM/MSH2</i> – 91471, <i>FH</i> – 38805, <i>FLCN</i> – 38806, <i>HOXB13</i> – 38807, <i>MEN1</i> – 93942, <i>MITF</i> – 38808, <i>MLH1</i> – 91460, <i>MSH6</i> – 91458, <i>MUTYH</i> – 93944, <i>NF1</i> – 93941, <i>PALB2</i> – 92571, <i>PMS2</i> – 91457, <i>PTEN</i> – 92566, <i>RET</i> – 93796, <i>SMARCA4</i> – 38809, <i>STK11</i> – 92565, <i>TP53</i> – 92560, <i>VHL</i> – 93943

* All panel components are available individually.

Understanding risk is the first step in addressing hereditary cancer


Hereditary cancer comprises about 5%-10% of all cancers

These potential red flags may indicate a higher risk for your patients:

- Cancer diagnosed at an early age
- Cancer in 2 or more closely related relatives
- Multiple generations in a family with cancer
- Multiple primary tumors in 1 person

Guideline-based quiz

A good place for your patients to start



Taking a simple online quiz at [QuestHereditaryCancer.com](https://www.questhereditarycancer.com) can help your patients better understand their risk of hereditary cancer.

Quest Advanced Oncology

Supporting you
and your patients
throughout their journey



We are committed to providing enhanced access to our hereditary cancer solutions



Complete portfolio of hereditary cancer tests—from comprehensive panels to single-gene tests



650+ MDs and PhDs as well as genetic counselors available for test consultation and results interpretation. Call 1.866.GENE.INFO (1.866.436.3463)



Specialty Testing Services team dedicated to saving you time and helping your patients access:

Insurance verification

- Our team will verify coverage and obtain preauthorization as required by your patient's health plan

Estimated patient responsibility

- We will communicate with your patients to make sure they understand what they're likely to owe before they commit to testing

Supplemental financial assistance program

- Limits out-of-pocket expenses to \$200 for qualified patients with income at or below 400% of the federal poverty level for qualified tests
- Qualified tests may be provided at no charge for patients who are uninsured or underinsured and who have household income at or below federal poverty level

The more you know about your patient's risk of hereditary cancer, the better you can navigate the next steps together. **Learn more at [QuestHereditaryCancer.com](https://www.questdiagnostics.com/questhereditarycancer)**

Test codes may vary by location. Please contact your local laboratory for more information.

Image content features models and is intended for illustrative purposes only.

[QuestDiagnostics.com](https://www.questdiagnostics.com)

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners.
© 2023 Quest Diagnostics Incorporated. All rights reserved. SB9691 03/2023



Quest Advanced
Oncology